MicrofluidX Demonstrate The Cyto Engine

Phacilitate
2 February 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Gene Therapy
Logistics
In this Tech Demo, James Kusena, Vice President of Bioprocessing and Applications at MicrofluidX, tells us about their core technology, The Cyto Engine, as seen at Advanced Therapies Week 2023.
The Cyto Engine addresses the difficulties of translating, manufacturing and commercialising cell therapies in a cost effective manner.
James explains how this technology has demonstrated to offer superior process efficiency, repeatability and cell health.
This demo has been produced in partnership with MicrofluidX.
![]() |
![]() |
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023